CN1310009A - Medicine for treating leucocytopenia caused by lupus erythematosus - Google Patents
Medicine for treating leucocytopenia caused by lupus erythematosus Download PDFInfo
- Publication number
- CN1310009A CN1310009A CN01104487A CN01104487A CN1310009A CN 1310009 A CN1310009 A CN 1310009A CN 01104487 A CN01104487 A CN 01104487A CN 01104487 A CN01104487 A CN 01104487A CN 1310009 A CN1310009 A CN 1310009A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- lupus erythematosus
- caused
- leucocytopenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 206010025135 lupus erythematosus Diseases 0.000 title claims abstract description 9
- 201000002364 leukopenia Diseases 0.000 title abstract description 8
- 229940079593 drug Drugs 0.000 title description 10
- 241000756943 Codonopsis Species 0.000 claims abstract description 7
- 241000222336 Ganoderma Species 0.000 claims abstract description 6
- 240000008669 Hedera helix Species 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 108010052008 colla corii asini Proteins 0.000 claims description 6
- 210000003038 endothelium Anatomy 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 230000000610 leukopenic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 235000010580 Psophocarpus tetragonolobus Nutrition 0.000 abstract 1
- 241000046198 Triteleia hyacinthina Species 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 231100001022 leukopenia Toxicity 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- KRTSDMXIXPKRQR-AATRIKPKSA-N monocrotophos Chemical compound CNC(=O)\C=C(/C)OP(=O)(OC)OC KRTSDMXIXPKRQR-AATRIKPKSA-N 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000020995 raw meat Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The medicine for treating leucocytopenia caused by lupus erythematosus and medicament is prepared with Codonopsis Pilosulae, Radix pseudostellariae, Atractylodis Macrocephalae, glossy ganoderma, white hyacinth bean and other Chinese medicinal materials. It has obvious curative effect.
Description
The present invention relates to a kind ofly treat that cell that lupus erythematosus and other immunological disease causes reduces or because of the medicine of drug-induced leukopenia.Specifically be with the Chinese herbal medicine be raw material according to the Chinese patent medicine that certain prepared forms, belong to the field of Chinese medicines.
Systemic lupus erythematosus (sle) is that world's medical matters circle are referred to as one of four big difficult disease of wrecking the human life, and domestic and international interrelated data report, the sickness rate that every year should disease to be rapidly increasing progressively by a relatively large margin, to the mankind's threat not second to cancer and acquired immune deficiency syndrome (AIDS).In areas such as the Luo Qisite of the U.S., California, the sickness rate in its members of the same clan exceeds hundreds of times of general crowd up to 0.4-5%.Black people's sickness rate is three times in general crowd, and in the Black women of 15-45, per 245 people have a people to suffer from lupus erythematosus, is more common in the 15-25 young women in year especially.Before not using the 17-hydroxy-11-dehydrocorticosterone treatment, the primary disease mortality rate is very high, 80% patient dies from primary disease in 2 years, in recent years because the progress of diagnostic techniques and utilization 17-hydroxy-11-dehydrocorticosterone, the utilization of immunosuppressant, levamisole, antiviral drugs, antilymphocyte globulin thymosin and Chinese herbal medicine, the primary disease mortality rate progressively descends, and best survival rate has reached 80-85% in present 10 years.Though change is arranged, but, still have the part patient to die from organa parenchymatosums such as the heart, kidney, the brain infringement and the complication of primary disease because of various factors, hormone and the immunosuppressant of using both at home and abroad brought potential infection and transition to use this type of medicine to suppress the normal immunologic function of body to patient at present, destroyed organism balance, the patient is caused a disease because of lupus erythematosus, is exactly to cause death because of side effects of pharmaceutical drugs.Particularly, systemic lupus erythematosus (sle) is the autoimmune disease that causes multiple organ injury, often causes leukopenia clinically, brings very big misery to patient, and lacks the active drug of the concurrent leukopenia of treatment lupus erythematosus on the market.
Therefore, the object of the invention provides a kind of medicine for the treatment of leucocytopenia caused by lupus erythematosus.
Medicine of the present invention is that the Chinese herbal medicine by the following weight proportioning forms according to certain prepared:
Radix Codonopsis 12-18
Radix Pseudostellariae 12-18
Semen Lablab Album 10-15
Ganoderma 12-18
Rhizoma Atractylodis Macrocephalae (parched) 10-15
Caulis Spatholobi 20-35
Fructus Ligustri Lucidi 12-18
Cortex Acanthopancis 12-18
Radix Rehmanniae 15-25
Radix Polygoni Multiflori 10-18
Stir-baked SQUAMA MANITIS 15-20
Radix Saposhnikoviae 10-15
Radix Astragali 15-25
Cornu Saigae Tataricae 6-15
Folium Perillae 10-15
Endothelium Corneum Gigeriae Galli 10-15
Colla Corii Asini 10-15
Medicine of the present invention preferably is prepared from by the Chinese medicine of following weight parts:
Radix Codonopsis 15
Radix Pseudostellariae 15
Semen Lablab Album 12
Ganoderma 15
Rhizoma Atractylodis Macrocephalae (parched) 12
Caulis Spatholobi 28
Fructus Ligustri Lucidi 15
Cortex Acanthopancis 15
The Radix Rehmanniae 20
The Radix Polygoni Multiflori 15
Stir-baked SQUAMA MANITIS 18
Radix Saposhnikoviae 12
The Radix Astragali 18
Cornu Saigae Tataricae 10
Folium Perillae 12
Endothelium Corneum Gigeriae Galli 12
Colla Corii Asini 12
In the middle of the above-mentioned raw materials medicine of the present invention, Cornu Saigae Tataricae can replace with Cornu Bubali.
Medicine of the present invention can be prepared into pharmaceutical dosage form commonly used clinically according to common process, preferred capsule.
Medicine of the present invention is on raw material is formed, and compatibility is reasonable, Radix Codonopsis, Radix Pseudostellariae, Semen Lablab Album, Rhizoma Atractylodis Macrocephalae (parched), Radix Astragali invigorating the spleen and benefiting QI in the side, and invigorating QI to consolidate the body surface resistance, the assistant Radix Saposhnikoviae is with the source of inspirationization life; The Radix Rehmanniae, Fructus Ligustri Lucidi, Caulis Spatholobi, the Radix Polygoni Multiflori, Colla Corii Asini nourishing blood are invigorated blood circulation, nourishing YIN and clearing heat; Cortex Acanthopancis closes the moon of the Radix Polygoni Multiflori, the flat invigorating the liver and kidney of Fructus Ligustri Lucidi; Cornu Saigae Tataricae symphysis ground, increasing the merit of heat-clearing and toxic substances removing, stir-baked SQUAMA MANITIS gas raw meat and scurrying, the property that it walks to scurry, very careful, so can declare logical internal organs, reach the pass key thoroughly, the modern medicine test confirms this product energy leukocyte increasing, and good hemostatic function is arranged, the Endothelium Corneum Gigeriae Galli promoting digestion and invigorating the stomach, to help the fortuneization of the efficacy of a drug, all medicines share, " qi being the governor of blood; blood is the dominator of QI " thought in invigorating the spleen and benefiting QI, giving young employees remedial-courses in general knowledge and vocational skills QI and blood, the traditional Chinese medical science, " spleen is for changing the source of angry blood ".Be used for the treatment of leukopenia with the clinical drug of above-mentioned preparation of compositions better curative effect is arranged.
Embodiment:
Choose raw material according to following composition
Radix Codonopsis 15
Radix Pseudostellariae 15
Semen Lablab Album 12
Ganoderma 15
Rhizoma Atractylodis Macrocephalae (parched) 12
Caulis Spatholobi 28
Fructus Ligustri Lucidi 15
Cortex Acanthopancis 15
The Radix Rehmanniae 20
The Radix Polygoni Multiflori 15
Stir-baked SQUAMA MANITIS 18
Radix Saposhnikoviae 12
The Radix Astragali 18
Cornu Saigae Tataricae 10
Folium Perillae 12
Endothelium Corneum Gigeriae Galli 12
Colla Corii Asini 12
With said medicine, pick up decontamination, clean, add water and do not have powder, decoct twice, each 1 hour, merge decoction liquor twice, concentrate fluid extract, add appropriate amount of starch, pelletize, tabletting promptly makes tablet.
Claims (2)
1, the leukopenic medicine of a kind of treatment caused by lupus erythematosus and other immunological disease is characterized in that this medicine is that Chinese medicine by following weight parts is prepared from:
Radix Codonopsis 12-18
Radix Pseudostellariae 12-18
Semen Lablab Album 10-15
Ganoderma 12-18
Rhizoma Atractylodis Macrocephalae (parched) 10-15
Caulis Spatholobi 20-35
Fructus Ligustri Lucidi 12-18
Cortex Acanthopancis 12-18
Radix Rehmanniae 15-25
Radix Polygoni Multiflori 10-18
Stir-baked SQUAMA MANITIS 15-20
Radix Saposhnikoviae 10-15
Radix Astragali 15-25
Cornu Saigae Tataricae 6-15
Folium Perillae 10-15
Endothelium Corneum Gigeriae Galli 10-15
Colla Corii Asini 10-15
2, medicine according to claim 1 is characterized in that this medicine is that Chinese medicine by following weight parts is prepared from:
Radix Codonopsis 15
Radix Pseudostellariae 15
Semen Lablab Album 12
Ganoderma 15
Rhizoma Atractylodis Macrocephalae (parched) 12
Caulis Spatholobi 28
Fructus Ligustri Lucidi 15
Cortex Acanthopancis 15
The Radix Rehmanniae 20
The Radix Polygoni Multiflori 15
Stir-baked SQUAMA MANITIS 18
Radix Saposhnikoviae 12
The Radix Astragali 18
Cornu Saigae Tataricae 10
Folium Perillae 12
Endothelium Corneum Gigeriae Galli 12
Colla Corii Asini 12
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB01104487XA CN1150015C (en) | 2001-02-27 | 2001-02-27 | Medicine for treating leucocytopenia caused by lupus erythematosus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB01104487XA CN1150015C (en) | 2001-02-27 | 2001-02-27 | Medicine for treating leucocytopenia caused by lupus erythematosus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1310009A true CN1310009A (en) | 2001-08-29 |
| CN1150015C CN1150015C (en) | 2004-05-19 |
Family
ID=4653943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB01104487XA Expired - Lifetime CN1150015C (en) | 2001-02-27 | 2001-02-27 | Medicine for treating leucocytopenia caused by lupus erythematosus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1150015C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100335096C (en) * | 2003-06-03 | 2007-09-05 | 霍玉书 | Anti-allergic traditional Chinese medicine composition and preparing method thereof |
-
2001
- 2001-02-27 CN CNB01104487XA patent/CN1150015C/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100335096C (en) * | 2003-06-03 | 2007-09-05 | 霍玉书 | Anti-allergic traditional Chinese medicine composition and preparing method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1150015C (en) | 2004-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1048498A (en) | The manufacture method of the compositions of treatment immunologic function deficiency disease | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN1111046C (en) | Chinese medicine preparation for curing postpartum disease of woman | |
| CN1051471C (en) | A kind of pharmaceutical composition for treating osteoporosis | |
| CN1107711A (en) | Hypoglycemic compound capsule | |
| CN1150015C (en) | Medicine for treating leucocytopenia caused by lupus erythematosus | |
| CN101199749A (en) | Chinese medicine for treating AIDS | |
| CN1139565A (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN1173718C (en) | Medicine for curing lupus erythematosus etc. immune diseases induced diseases | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN1136939A (en) | Chinese drugs for curing hepatitis B | |
| CN1569095A (en) | Medicine for treating cerebral infarction | |
| CN1195541C (en) | Medicine combination for treating chronic hepatitis B | |
| CN1055021C (en) | Chinese medicine capsule for nephritis | |
| CN1190229C (en) | Medicine for curing hepatitis B | |
| CN1269518C (en) | Compound medicine for treating tuberculosis and its preparing method | |
| CN1059590C (en) | Medicine for blood generation and preparing method | |
| CN1150016C (en) | Medicine for treating fever caused by lupus erythematosus and other immunological disease | |
| CN1470271A (en) | Chinese medicinal compound preparation for treating liver fibrillation disease and its preparation method | |
| CN1212150C (en) | Medicine for treating virus hepatitis and its preparation method | |
| CN1150014C (en) | Lupus erythematosus treating medicine | |
| CN1309412C (en) | Medicine composition for treating AIDS and preparing method thereof | |
| CN1183297A (en) | Katsutoxin pill for tumor and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20040519 |